Title:
USES OF COMPOUND IN PREPARATION OF DRUGS FOR TREATING BRAIN GLIOMA
Document Type and Number:
WIPO Patent Application WO/2017/114249
Kind Code:
A1
Abstract:
The present invention provides uses of a compound represented by formula A in the preparation of drugs for treating brain glioma and particularly glioblastoma. Particularly provided are uses of the compound represented by formula A in the preparation of drugs for treating expression of specific fusion protein. By means of the technical solution of the present invention, typing of brain glioblastoma can be implemented, a drug administration can be carried out for a specific patient group, and precise treatment can be implemented.
More Like This:
Inventors:
JIANG TAO (CN)
LIU YANWEI (CN)
HU HUIMIN (CN)
SHI HEPENG (CN)
XUE WEIZHE (CN)
LIU YANWEI (CN)
HU HUIMIN (CN)
SHI HEPENG (CN)
XUE WEIZHE (CN)
Application Number:
PCT/CN2016/111227
Publication Date:
July 06, 2017
Filing Date:
December 21, 2016
Export Citation:
Assignee:
BEIJING PEARL BIOTECHNOLOGY LTD LIABILITY COMPANY (CN)
BEIJING NEUROSURGICAL INST (CN)
BEIJING NEUROSURGICAL INST (CN)
International Classes:
C07D487/04; A61K31/433; A61K31/437; A61K31/5025; A61K31/519; A61K31/5377; C07D471/04; C07D513/04
Foreign References:
| CN102448968A | 2012-05-09 | |||
| CN103122000A | 2013-05-29 | |||
| US20110294849A1 | 2011-12-01 | |||
| US20060009493A1 | 2006-01-12 | |||
| CN103122000A | 2013-05-29 |
Other References:
BAO, Z. S. ET AL.: "RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas", GENOME RES., vol. 24, no. 11, 18 August 2014 (2014-08-18), pages 1765 - 1773, XP055202258
CHEN, H. M. ET AL.: "Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions", FEBS LETTERS, vol. 589, no. 13, 29 April 2015 (2015-04-29), pages 1437 - 1443, XP055507079
MARTENS, T. ET AL.: "A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo", CLINICAL CANCER RESEARCH, vol. 12, no. 20, 15 October 2006 (2006-10-15), pages 6144 - 6152, XP002618391
WEN, P.Y. ET AL.: "A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma", NEURO-ONCOLOGY, vol. 13, no. 4, 4 February 2011 (2011-02-04), pages 437 - 446, XP055084095
CHEN, H. M. ET AL.: "Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions", FEBS LETTERS, vol. 589, no. 13, 29 April 2015 (2015-04-29), pages 1437 - 1443, XP055507079
MARTENS, T. ET AL.: "A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo", CLINICAL CANCER RESEARCH, vol. 12, no. 20, 15 October 2006 (2006-10-15), pages 6144 - 6152, XP002618391
WEN, P.Y. ET AL.: "A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma", NEURO-ONCOLOGY, vol. 13, no. 4, 4 February 2011 (2011-02-04), pages 437 - 446, XP055084095
Attorney, Agent or Firm:
LEADING INTELLECTUAL PROPERTY FIRM (CN)
Download PDF: